Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study assessed the use of oral finasteride in transgender men with androgenetic alopecia and found that all patients improved by one grade on the Norwood–Hamilton scale within about 5.5 months, with no significant adverse effects reported during the 16.2 months of follow-up.

This review discusses the adverse events associated with 5-alpha reductase inhibitors, finding them generally well-tolerated but noting potential risks like sexual side effects and psychological effects in men, and sparse data on use in women.

In this study, finasteride was found to be more effective than 5% minoxidil for treating male androgenetic alopecia in Chinese patients, with combination therapy showing the greatest improvement.

This study found that a combination of topical minoxidil and finasteride helped maintain hair density in patients with androgenetic alopecia after initial oral finasteride treatment.

This study found that both finasteride and dutasteride effectively increased hair thickness in women with androgenetic alopecia over three years, with dutasteride performing better in women under 50 at specific scalp sites.

This study found no statistically significant association between the use of 5α-reductase inhibitors and male breast cancer incidence.

This article investigates whether finasteride influences adult hippocampal neurogenesis related to depression and reports no new clinical findings; the authors suggest further research on its neurosteroid inhibition.

Using finasteride with TIP extends time off period for prostate cancer patients.

This study found that both finasteride and flutamide effectively reduced hirsutism, with flutamide being more effective than finasteride in decreasing hirsutism scores and hair diameter over 12 months.

Clinical studies reported that finasteride reduces scalp dihydrotestosterone levels and improves hair growth in men with androgenetic alopecia, supporting its role as a treatment option.

This study found that nearly half of men using finasteride reported clinically significant depression, highlighting the need for psychiatric screening and careful risk assessment by prescribing clinicians.

This study provides the first crystal structure of the human SRD5A2 enzyme, revealing key insights into its function and inhibition which may aid future drug development.

This review discusses the evidence for post-finasteride syndrome as a condition potentially induced by finasteride and dutasteride, associating them with sexual dysfunction, depression, anxiety, and suicidal ideation in a subset of men, and reports no new clinical results.

This study found that using drug microplates in transdermal finasteride films enhances aqueous solubility and skin permeation compared to films with pure finasteride.

In this study of men with androgenetic alopecia, daily finasteride 1 mg alongside hair transplant improved scalp hair density and growth of nontransplanted hair compared to placebo over 48 weeks.

Finasteride can cause one-sided breast enlargement, which disappears after stopping the drug.

Combination therapy improves urinary flow and reduces residual urine, but needs better stent design.

In this study, men with AGA who took finasteride 5 mg daily for 24 months showed a significant increase in hair counts compared to those who received a placebo.

This study found that lowering serum DHT levels with 5 mg finasteride daily did not significantly alter serum gonadotropin levels in healthy young men after 28 days.

This case report suggests a possible association between long-term finasteride use for male pattern baldness and the development of cataracts and intraoperative floppy-iris syndrome in a patient.

This review discusses the limited objective evidence for using finasteride in women with alopecia, suggesting that it could be considered for those who don't benefit from minoxidil, but reports no new clinical results.

This report describes two cases of gynecomastia linked to the use of Finasteride (Propecia®) for treating androgenetic alopecia, highlighting a rare but important side effect.

This study found that an intermittent low-dose regimen of finasteride (2.5 mg every 3 days) effectively reduced hirsutism scores in women with idiopathic hirsutism or polycystic ovary syndrome, with fewer side effects than continuous daily administration.

Finasteride reduces alcohol withdrawal effects, especially in female mice.

This review concluded that finasteride may reduce hirsutism scores and hair diameter in women with hyperandrogenism, but concerns about teratogenicity and long-term safety make it a secondary treatment option.

This study developed a fully automated HPLC method for accurately quantifying finasteride in human plasma, achieving a detection limit of 1 ng/ml with validated application in pharmacokinetic studies.

This study developed a theoretical model that suggests finasteride may completely inhibit 5AR type 2, but not sufficiently suppress type 1, leading to only partial reduction of dihydrotestosterone at clinical doses.

In this study, finasteride treatment did not negatively impact bone development or density in male rats, suggesting that DHT deficiency is not harmful to the male rat skeleton.

This study found that freeze-dried finasteride nanoparticles improved the stability, solubility, and in vitro dissolution of the drug, indicating potential benefits for poorly water-soluble drugs.

This paper suggests that ketoconazole 2% shampoo may enhance finasteride's effectiveness in treating androgenetic alopecia by more completely inhibiting the dihydrotestosterone pathway.